Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Trading 04-30 10:09:09 EDT

1.92

+0.08

+4.35%

High1.94	Low1.86	Vol107.70K
Open1.94	D1 Closing1.84	Amplitude4.35%
Mkt Cap66.30M	Tradable Cap58.44M	Total Shares34.53M
T/O205.33K	T/O Rate0.35%	Tradable Shares30.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.92,"timestamp":1777558129975,"preClose":1.84,"halted":0,"volume":107703,"delay":0,"changeRate":0.04347826086956513,"floatShares":30437600,"shares":34532400,"eps":-1.40396,"marketStatus":"Trading","change":0.08,"latestTime":"04-30 10:09:09 EDT","open":1.94,"high":1.94,"low":1.86,"amount":205332.5707209,"amplitude":0.043478,"askPrice":1.93,"askSize":100,"bidPrice":1.92,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.40396,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777579200000},"marketStatusCode":2,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.84,"latestTime":"08:00 EDT","volume":100,"amount":184,"timestamp":1777550429125,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.8473,"preClose":1.84,"latestTime":"18:03 EDT","volume":373,"amount":688.145,"timestamp":1777500198539,"change":0.0073,"changeRate":0.003967,"amplitude":0.003967},"volumeRatio":1.044411,"impliedVol":2.3856,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/ANVS/tweets","defaultTab":"tweets","newsList":[{"id":"2630301145","title":"Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2630301145","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630301145?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:00","pubTimestamp":1777377600,"startTime":"0","endTime":"0","summary":"Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282572/0/en/Annovis-Publishes-Phase-2-3-Alzheimer-s-Trial-Results-in-Nature-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","PD","LU1169590202.USD","LU1169589451.USD","BK4132","ANVS","BK4023","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627644032","title":"Annovis Bio Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2627644032","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627644032?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:13","pubTimestamp":1776179580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 11:13 ET (15:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626359190","title":"Annovis Bio raises USD 10 million in underwritten public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2626359190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626359190?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:31","pubTimestamp":1775824278,"startTime":"0","endTime":"0","summary":"Annovis Bio closed an underwritten public offering that raised about USD 10 million in gross proceeds.Cash runway now extends through Q2 2027, including existing cash and a USD 1.5 million board-chair investment.Funding supports Phase 3 Alzheimer’s program for buntanetap, with 6-month symptomatic data expected in Q1 2027.Phase 3 Alzheimer’s trial is 75% enrolled; Parkinson’s open-label extension study is 28% enrolled.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3PMj2H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","ANVS","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","BK4139","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191834","title":"Annovis Bio Prices Registered Direct Offering to Fund Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626191834?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:38","pubTimestamp":1775817518,"startTime":"0","endTime":"0","summary":"An announcement from Annovis Bio ( ($ANVS) ) is now available. On April 9, 2026, Annovis Bio priced an underwritten registered direct offering of 5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-prices-registered-direct-offering-to-fund-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-prices-registered-direct-offering-to-fund-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626231134","title":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman","url":"https://stock-news.laohu8.com/highlight/detail?id=2626231134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626231134?lang=en_us&edition=fundamental","pubTime":"2026-04-10 01:51","pubTimestamp":1775757106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-FormanWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a6220b127d3bbee7041552a4a4e77ac3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL6N40S0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","ADSK","BLSG","WW","IDYA","AMZN","CORD","SMPL","VNDA","CRWG","WSR","NOC","ANVS","AZYY","FDX","TSLL","TSL","TSLA","TSLO","OXY","TSLQ","TSLI","TSLG","TSLS","MRVL","BLSH","BLSX","TEMT","TSLR","CCCC","CRSH","NOW","KYMR","MRVU","STAA","HRL","FBRX","RELL","CAT","GDRX","MVLL","NRGV","APLD","NUAI","CRWV","GLMD","CG","TEM","STZ","CRWU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626827861","title":"BRIEF-Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626827861","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626827861?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:46","pubTimestamp":1775738804,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Announces $10 Million Underwritten Offering Of Common Stock And Accompanying WarrantsApril 9 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS ANNOUNCES $10 MILLION UNDERWRITTEN OFFERING OF COM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA5TYFTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626218251","title":"Annovis Bio prices USD 10 million stock offering with warrants at USD 1.9 unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2626218251","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626218251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:33","pubTimestamp":1775738039,"startTime":"0","endTime":"0","summary":"Annovis Bio priced an underwritten follow-on offering of 5,263,156 common shares with warrants to buy up to 5,263,156 additional shares.Offering price set at USD 1.9 for each share-warrant package.Warrants carry an exercise price of USD 2.5 per share, become exercisable six months after issuance, expire 5.5 years from issuance.Gross proceeds expected at about USD 10 million, excluding any warrant exercise proceeds.Net proceeds earmarked for Phase 3 development of buntanetap in Alzheimer’s disease, working capital, general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6t0Gss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2T93.GBP","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","ANVS","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","NDAQ","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182392","title":"Annovis Bio Inc - Combined Offering Price per Share and Warrant Is $1.90","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182392?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA5TYFTG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626874261","title":"Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626874261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626874261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PD","BK4132","ANVS","BK4023","LU1169590202.USD","LU1169589451.USD","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624693140","title":"Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624693140","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624693140?lang=en_us&edition=fundamental","pubTime":"2026-04-04 10:02","pubTimestamp":1775268179,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on April 3, 2026. Director Michael B. Hoffman has significantly increased his stake...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664066","title":"Annovis Bio director Michael B. Hoffman buys $1.5 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664066","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664066?lang=en_us&edition=fundamental","pubTime":"2026-04-04 05:07","pubTimestamp":1775250427,"startTime":"0","endTime":"0","summary":"Annovis Bio director Michael B. Hoffman bought 713,800 common shares at USD 2.1 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL9RRyD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio director Michael B. Hoffman buys $1.5 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505517","title":"Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505517","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505517?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129428,"startTime":"0","endTime":"0","summary":"Annovis Bio secured U.S. Patent No. 12,582,632 B2 covering use of buntanetap to prevent or treat neurological injuries linked to brain infections.Patent claims include preventive use in at-risk healthy individuals.Claims also cover treatment intended to reverse neurological damage in infected patients.Buntanetap is Annovis’ Phase 3 oral drug candidate for Alzheimer’s disease and Parkinson’s disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3rJNsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","BK4112","BK4139","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","ANVS","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623584887","title":"Annovis Publishes Historical Review of Buntanetap in The Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2623584887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623584887?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265424/0/en/Annovis-Publishes-Historical-Review-of-Buntanetap-in-The-Scientist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","LU1169590202.USD","ANVS","PD","LU1169589451.USD","BK4139","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622700720","title":"Annovis Bio Inc - CEO Maria Maccecchini to Serve as Acting CFO Until Replacement Is Identified - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622700720","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622700720?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:20","pubTimestamp":1774473604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D18W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622202007","title":"Annovis Bio Inc - Mark Guerin Steps Down as CFO Effective March 23, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622202007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622202007?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:20","pubTimestamp":1774473604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007478","title":"Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini becomes acting CFO effective March 23, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007478","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007478?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:19","pubTimestamp":1774473582,"startTime":"0","endTime":"0","summary":"Mark Guerin is no longer employed as CFO at Annovis Bio, effective March 23, 2026.His departure was not related to any disagreement over the company’s operations, policies, or practices.The board is expected to appoint CEO Maria Maccecchini as acting CFO while a replacement is identified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL8Jlkrg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620192247","title":"Annovis Bio enters partnership with NeuroRPM","url":"https://stock-news.laohu8.com/highlight/detail?id=2620192247","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620192247?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:56","pubTimestamp":1773921406,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced a partnership with NeuroRPM to implement a new FDA-cleared artificial intelligence platform that collects movement dat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-enters-partnership-with-neurorpm-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-enters-partnership-with-neurorpm-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242663","title":"Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242663","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242663?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:31","pubTimestamp":1773919878,"startTime":"0","endTime":"0","summary":"Annovis partnered with NeuroRPM to use NeuroRPM’s FDA-cleared wearable platform for digital biomarker monitoring in Annovis’s ANVS-25002 open-label Parkinson’s disease clinical trial.The NeuroRPM platform uses Apple Watch data to passively collect and analyze movement during daily activities.Monitoring is intended to provide continuous measurement of Parkinson’s motor symptoms including bradykinesia, tremor, and dyskinesia.The ANVS-25002 study is expected to enroll about 500 participants across multiple clinical sites, with eligible participants able to opt into the digital monitoring program.After the study, participants may continue using NeuroRPM for clinical monitoring by prescription.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL743Hj0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","LU2210149790.SGD","IE00BN0W2W23.USD","ANVS","LU2095319765.USD","SG9999014005.SGD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620425092","title":"Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425092","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425092?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:31","pubTimestamp":1773919876,"startTime":"0","endTime":"0","summary":"Annovis partnered with NeuroRPM to deploy an FDA-cleared AI platform for movement-data collection in an ongoing Parkinson’s disease study.The platform is intended to monitor bradykinesia, tremor, and dyskinesia using mobile and wearable applications.Annovis said the NeuroRPM data will be used as a digital biomarker to track symptom changes during the study.The open-label study is enrolling across 25 U.S. sites and is designed to evaluate buntanetap over 36 months.The trial has enrolled 90 of an estimated 500 participants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8Cf2jr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","ANVS","LU0314104364.USD","BK4112","SG9999014039.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242523","title":"Neurorpm to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242523?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA6SBNBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0846},{"period":"3month","weight":-0.3452},{"period":"6month","weight":-0.1238},{"period":"1year","weight":0.2517},{"period":"ytd","weight":-0.4682}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040659},{"month":2,"riseRate":0.285714,"avgChangeRate":0.058949},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.056117},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.140572},{"month":5,"riseRate":0.666667,"avgChangeRate":0.302491},{"month":6,"riseRate":0.5,"avgChangeRate":0.167707},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098191},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070358},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.058484},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.073043},{"month":11,"riseRate":0.666667,"avgChangeRate":0.26823},{"month":12,"riseRate":0.333333,"avgChangeRate":0.124011}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}